Sanofi: Diabetes Mellitus trials
The registry lists 33 Diabetes Mellitus studies with Sanofi as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 7Phase 2 2Phase 3 12Phase 4 10No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Sotagliflozin Multiple-dose Study in Healthy Chinese SubjectsCompletedNCT03909451Phase 1
- Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.CompletedNCT03703869
- Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate HypertensionCompletedNCT03462069Phase 2
- A Drug-Drug Interaction Study Between Sotagliflozin and RamiprilCompletedNCT03414723Phase 1
- A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy SubjectsCompletedNCT03174548Phase 1
- Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03070678Phase 1
- Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of SotagliflozinCompletedNCT03063580Phase 1
- Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With InsulinCompletedNCT02082028Not applicable
- Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood GlucoseCompletedNCT02073188Phase 3
- Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)CompletedNCT00642915Phase 4
- Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of GlimepirideCompletedNCT00633425Phase 4
- The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning DosingCompletedNCT00609895Phase 4
- Extension to Study HMR1964A/3011 in BelgiumCompletedNCT00576862Phase 4
- An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical PracticeCompletedNCT00576368Phase 4
- Insulin Glargine, INITIATE Metabolic and Economic Outcomes of LantusCompletedNCT00565162Phase 4
- PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+LisproCompletedNCT00540709Phase 4
- Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes MellitusCompletedNCT00526513Phase 4
- Dose-effect of SSR180575 in Diabetic NeuropathyCompletedNCT00502515Phase 2
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and ExerciseTerminatedNCT00478972Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic DrugTerminatedNCT00478595Phase 3
- Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes MellitusCompletedNCT00467376Phase 3
- A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 DiabetesTerminatedNCT00449605Phase 3
- Lantus in PrediabetesCompletedNCT00348972Phase 1
- LANCGMS - Lantus Continuous Glucose Monitoring SubcutaneousCompletedNCT00322075Phase 4
- Insulin Glulisine in Healthy Lean and Obese SubjectsCompletedNCT00311077Phase 1
- Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes MellitusCompletedNCT00290979Phase 3
- Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes MellitusCompletedNCT00290927Phase 3
- Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic PatientsCompletedNCT00174824Phase 4
- Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)CompletedNCT00135941Phase 3
- Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and AdolescentsCompletedNCT00115570Phase 3
- Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes AdolescentsCompletedNCT00046501Phase 3
- Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other TreatmentCompletedNCT00046462Phase 3
- Obese Patients With Type 2 DiabetesCompletedNCT00029848Phase 3